Nakom (Levodopa, Carbidopa Monohydrate)

Nakom is an antiparkinson agent that acts on dopaminergic pathways to improve motor function in Parkinsonian disorders.

• Parkinson's disease: alleviates bradykinesia, rigidity, and tremor.
• Parkinsonian syndrome: restores dopamine levels to improve motor symptoms.
• Secondary Parkinsonism: helps control movement abnormalities associated with drug‑induced or vascular Parkinsonism.

• Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine, directly augmenting central dopaminergic activity. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, preventing premature conversion of levodopa outside the brain, thereby increasing its availability to the central nervous system and reducing peripheral side effects.

Levodopa/carbidopa therapy may be associated with a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Orthostatic hypotension: dizziness upon standing.
• Headache: transient cranial discomfort.
• Insomnia: difficulty initiating sleep.
• Dyspepsia: indigestion or stomach discomfort.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Dyskinesia: involuntary, erratic movements.
• Psychosis: hallucinations or delusional thinking.
• Severe hypotension: marked blood pressure drop requiring medical attention.
• Cardiac arrhythmia: irregular heart rhythm.
• Neuroleptic malignant syndrome: rare but life‑threatening reaction.

Before initiating therapy, consider the following safety measures.

• Dose titration: start with the lowest effective dose and increase gradually under medical supervision.
• Blood pressure monitoring: watch for orthostatic hypotension, especially in the elderly.
• Psychiatric assessment: monitor for emergence or worsening of psychotic symptoms.
• Dietary considerations: avoid high‑protein meals around dosing times as they may reduce levodopa absorption.
• Storage: keep at ambient temperature below 25 °C; retain in the original container, protect from moisture and light.

Levodopa/carbidopa can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis.
• Antipsychotics (e.g., haloperidol): may diminish antiparkinson efficacy.
• Iron or calcium supplements: can markedly reduce levodopa absorption.

Moderate Interactions (Monitor Closely)

• Antihypertensives: additive hypotensive effect may require dose adjustment.
• SSRIs or SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors.
• High‑protein diet: may compete with levodopa for transport across the gut wall, lowering plasma levels.